On May 22, 2017 IPHARMA received the Ministry of Health permission to conduct clinical trial of Phase I of the drug XC221. Protocol #ARI-XC221-01 "Double-blind randomized placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics...
On December, 14th at 11:00 am , we will hold a webinar on the “Phase I and Bioequivalence clinical trials” . Early phase studies is the most important stage of the drug development process. Firstly, volunteers and patients take medicine for the...